omeprazole has been researched along with indican in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffmann, M; Liu, H; Narayanan, R; Surapaneni, S | 1 |
| Chen, X; Jiang, H; Lu, S; Ma, Z; Xu, S; Yang, X; Zhang, Y; Zhao, J; Zhou, H | 1 |
2 other study(ies) available for omeprazole and indican
| Article | Year |
|---|---|
The Uremic Toxin Indoxyl-3-Sulfate Induces CYP1A2 In Primary Human Hepatocytes.
Topics: Adult; Aged; Cells, Cultured; Cytochrome P-450 CYP1A2; Dose-Response Relationship, Drug; Female; Hepatocytes; Humans; Indican; Indoleacetic Acids; Male; Omeprazole; Renal Insufficiency, Chronic; RNA, Messenger; Uremia | 2016 |
Proton pump inhibitor-induced risk of chronic kidney disease is associated with increase of indoxyl sulfate synthesis via inhibition of CYP2E1 protein degradation.
Topics: Animals; Cytochrome P-450 CYP2E1; Indican; Lansoprazole; Mice; Omeprazole; Pantoprazole; Proteolysis; Proton Pump Inhibitors; Renal Insufficiency, Chronic; Uremic Toxins | 2022 |